---
title: "\"Performance\" NT PHARMA's annual loss narrowed to 26.041 million RMB, no dividend distribution"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281276430.md"
description: "NT PHARMA announced its 2025 annual performance, with revenue of RMB 24.158 million, a year-on-year decrease of 36.4%. The loss narrowed from RMB 53.357 million in the same period of 2024 to RMB 26.041 million; the loss per share is 4.22 cents. No final dividend is declared"
datetime: "2026-04-01T00:47:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281276430.md)
  - [en](https://longbridge.com/en/news/281276430.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281276430.md)
---

# "Performance" NT PHARMA's annual loss narrowed to 26.041 million RMB, no dividend distribution

NT PHARMA (01011.HK) announced its performance for the fiscal year 2025, with revenue of RMB 24.158 million, a year-on-year decrease of 36.4%. The loss narrowed from RMB 53.357 million in the same period of 2024 to RMB 26.041 million; the loss per share is 4.22 cents. No final dividend is declared

### Related Stocks

- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [510660.CN](https://longbridge.com/en/quote/510660.CN.md)
- [588130.CN](https://longbridge.com/en/quote/588130.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)
- [159929.CN](https://longbridge.com/en/quote/159929.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [01011.HK](https://longbridge.com/en/quote/01011.HK.md)
- [512010.CN](https://longbridge.com/en/quote/512010.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [589720.CN](https://longbridge.com/en/quote/589720.CN.md)

## Related News & Research

- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [China NT Pharma Says Director’s Judicial Records Tied to Settled Subsidiary Loan, No Material Impact Seen](https://longbridge.com/en/news/286577625.md)
- [Shanghai Henlius says China regulator clears HLX48 Phase 1 trial IND for solid tumors](https://longbridge.com/en/news/287189347.md)
- [CK Life Sciences shareholders pass AGM resolutions on director elections, mandates](https://longbridge.com/en/news/287189492.md)